Early treatment consideration in patients with hepatitis B āeā antigen-positive chronic infection: is it time for a paradigm shift?
, U.K. & Hong Kong
- 12p.
- Viruses Vol. 4 (5) .
To date, antiviral therapy has been reserved for patients with ostensibly active liver disease, fibrosis or cirrhosis, and/or increased risk of HCC. Historically, patients with hepatitis B āeā antigen (HBeAg)-positive chronic infection, were not offered antiviral therapy. The current review discusses the reasons to consider early antiviral therapy in HBeAg-positive chronic infection.